Novavax Files 8-K with Financials and Other Events
Ticker: NVAX · Form: 8-K · Filed: Nov 12, 2024 · CIK: 1000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, disclosure
Related Tickers: NVAX
TL;DR
Novavax dropped an 8-K on 11/11 with financials and other news.
AI Summary
On November 11, 2024, Novavax, Inc. filed an 8-K report detailing a Regulation FD Disclosure and other events. The filing also includes financial statements and exhibits. The company's principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland.
Why It Matters
This 8-K filing provides an update on Novavax's corporate activities and financial reporting, which is crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K report and does not appear to contain any immediately alarming or significant negative news.
Key Players & Entities
- Novavax, Inc. (company) — Registrant
- November 11, 2024 (date) — Date of earliest event reported
- 700 Quince Orchard Road, Gaithersburg, Maryland 20878 (location) — Principal Executive Offices
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of this disclosure are not provided in the provided text snippet.
What types of financial statements and exhibits are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these statements and exhibits is not detailed in the provided text.
When was Novavax, Inc. incorporated and in which jurisdiction?
Novavax, Inc. was incorporated in Delaware.
What is Novavax's IRS Employer Identification Number?
Novavax's IRS Employer Identification Number is 22-2816046.
What is the SIC code for Novavax, Inc.?
The Standard Industrial Classification (SIC) code for Novavax, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 610 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-11-12 11:21:24
Key Financial Figures
- $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
Filing Documents
- tm2428029d1_8k.htm (8-K) — 28KB
- tm2428029d1_ex99-1.htm (EX-99.1) — 13KB
- tm2428029d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-116593.txt ( ) — 217KB
- nvax-20241111.xsd (EX-101.SCH) — 3KB
- nvax-20241111_lab.xml (EX-101.LAB) — 33KB
- nvax-20241111_pre.xml (EX-101.PRE) — 22KB
- tm2428029d1_8k_htm.xml (XML) — 3KB
01. Regulation FD
Item 7.01. Regulation FD Disclosure. On November 11, 2024, Novavax, Inc. ("Novavax") issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in Item 7.01 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration except as shall be expressly set forth by specific reference in such filing. In addition, the contents of Novavax's website are not incorporated by reference into this Current Report on Form 8-K and you should not consider information provided on Novavax's website to be part of this Current Report on Form 8-K.
01. Other Events
Item 8.01. Other Events. On October 16, 2024, Novavax disclosed that the U.S. Food and Drug Administration ("FDA") had placed a clinical hold on Novavax's Investigational New Drug Application ("IND") for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. On November 11, 2024, Novavax announced that the FDA has removed the previously disclosed clinical hold on Novavax's IND for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated November 11, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: November 11, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary